Melbourne, Australia, 22 October 2025 – ENA Respiratory, a clinical-stage pharmaceutical company developing antiviral host defense enhancers to minimize the impact of symptomatic viral respiratory infections, announces today that it has raised US$22.4m (AUD$34m) in its Series B financing. The Company welcomed new investment from the Gates Foundation and the previously announced contribution from Flu […]
http://enarespiratory.com/wp-content/uploads/2024/10/Ena_Respiratory_RGB_Color_REV.svg00Chris Kellyhttp://enarespiratory.com/wp-content/uploads/2024/10/Ena_Respiratory_RGB_Color_REV.svgChris Kelly2025-10-22 04:57:592025-10-24 23:00:54ENA Respiratory Attracts US$22.4m (AU$34m) to Fund Phase II Development of INNA-051 Nasal Spray Designed to Protect Against Symptomatic Viral Respiratory Infections
Melbourne, Australia, 6 May 2025 – ENA Respiratory, a clinical-stage pharmaceutical company developing antiviral host defence enhancers to minimize the impact of viral respiratory infections, announces today that it has appointed Kenny Simmen PhD and Alison Humbles PhD as Strategic Advisors. Dr Simmen and Dr Humbles bring decades of experience gained in big pharma, specifically […]
http://enarespiratory.com/wp-content/uploads/2024/10/Ena_Respiratory_RGB_Color_REV.svg00Chris Kellyhttp://enarespiratory.com/wp-content/uploads/2024/10/Ena_Respiratory_RGB_Color_REV.svgChris Kelly2025-05-06 08:38:352025-05-06 08:38:35ENA Respiratory Appoints International Pharma Experts as Strategic Advisors to Support Development of INNA-051 Antiviral Host Defence Enhancer
Phase 2 to evaluate safety, tolerability and efficacy of INNA-051 in the prevention of illness due to viral respiratory infections Study to be led by global health physician scientist, Dr. Justin Ortiz, Professor of Medicine at the University of Maryland School of Medicine Melbourne, Australia, 9 April 2025 – ENA Respiratory, a clinical-stage pharmaceutical company […]
http://enarespiratory.com/wp-content/uploads/2024/10/Ena_Respiratory_RGB_Color_REV.svg00Chris Kellyhttp://enarespiratory.com/wp-content/uploads/2024/10/Ena_Respiratory_RGB_Color_REV.svgChris Kelly2025-04-09 08:26:102025-04-09 08:26:10ENA Respiratory Partners with University of Maryland and Leading Respiratory Disease Expert to Conduct Phase 2 Study of INNA-051 Antiviral Host Defence Enhancer
Clinical studies demonstrated that INNA-051’s natural defence boosting mechanism is effective in older adults Administration of INNA-051 to older adults (65 years old) in a Phase 1 study was well-tolerated and increased important antiviral host-defence pathways Pre-clinical data demonstrated reduced influenza virus dissemination to the lungs of aged mice, consistent with results from studies in […]
http://enarespiratory.com/wp-content/uploads/2024/10/Ena_Respiratory_RGB_Color_REV.svg00Chris Kellyhttp://enarespiratory.com/wp-content/uploads/2024/10/Ena_Respiratory_RGB_Color_REV.svgChris Kelly2025-04-02 07:39:382025-04-02 07:39:38ENA Respiratory Announces Publication Supporting the Potential of its Novel Intranasal Therapy INNA-051 to Reduce the Impact of Viral Respiratory Infections in Older Adults
Melbourne, Australia, 10 February 2025 – ENA Respiratory, a clinical-stage pharmaceutical company developing antiviral host defence immune enhancers to minimize the impact of viral respiratory infections, announces today it has received a US$5 million investment from Flu Lab. Flu Lab, a California-based organization founded to advance innovative approaches for the prevention and treatment of influenza, […]
http://enarespiratory.com/wp-content/uploads/2024/10/Ena_Respiratory_RGB_Color_REV.svg00Chris Kellyhttp://enarespiratory.com/wp-content/uploads/2024/10/Ena_Respiratory_RGB_Color_REV.svgChris Kelly2025-02-10 08:01:272025-02-10 08:01:27ENA Respiratory Receives US$5m Investment from Flu Lab to Support Clinical Development of Novel Intranasal Antiviral Host Defence Immune Enhancer, INNA-051
Publication comes as the prevalence of respiratory infections continues to rise worldwide Melbourne, Australia, 28 January 2025 – ENA Respiratory, a clinical-stage pharmaceutical company developing antiviral host defense immune enhancers to minimize the impact of respiratory viral infections in at-risk populations, announces today the publication of an invited review of the preclinical and clinical development […]
http://enarespiratory.com/wp-content/uploads/2024/10/Ena_Respiratory_RGB_Color_REV.svg00Chris Kellyhttp://enarespiratory.com/wp-content/uploads/2024/10/Ena_Respiratory_RGB_Color_REV.svgChris Kelly2025-01-28 03:25:282025-01-28 08:07:34ENA Respiratory Publishes Review of Development of Novel Intranasal Antiviral Host Defense Immune Enhancer INNA-051 in Antiviral Research
ENA Respiratory Attracts US$22.4m (AU$34m) to Fund Phase II Development of INNA-051 Nasal Spray Designed to Protect Against Symptomatic Viral Respiratory Infections
Melbourne, Australia, 22 October 2025 – ENA Respiratory, a clinical-stage pharmaceutical company developing antiviral host defense enhancers to minimize the impact of symptomatic viral respiratory infections, announces today that it has raised US$22.4m (AUD$34m) in its Series B financing. The Company welcomed new investment from the Gates Foundation and the previously announced contribution from Flu […]
ENA Respiratory Appoints International Pharma Experts as Strategic Advisors to Support Development of INNA-051 Antiviral Host Defence Enhancer
Melbourne, Australia, 6 May 2025 – ENA Respiratory, a clinical-stage pharmaceutical company developing antiviral host defence enhancers to minimize the impact of viral respiratory infections, announces today that it has appointed Kenny Simmen PhD and Alison Humbles PhD as Strategic Advisors. Dr Simmen and Dr Humbles bring decades of experience gained in big pharma, specifically […]
ENA Respiratory Partners with University of Maryland and Leading Respiratory Disease Expert to Conduct Phase 2 Study of INNA-051 Antiviral Host Defence Enhancer
Phase 2 to evaluate safety, tolerability and efficacy of INNA-051 in the prevention of illness due to viral respiratory infections Study to be led by global health physician scientist, Dr. Justin Ortiz, Professor of Medicine at the University of Maryland School of Medicine Melbourne, Australia, 9 April 2025 – ENA Respiratory, a clinical-stage pharmaceutical company […]
ENA Respiratory Announces Publication Supporting the Potential of its Novel Intranasal Therapy INNA-051 to Reduce the Impact of Viral Respiratory Infections in Older Adults
Clinical studies demonstrated that INNA-051’s natural defence boosting mechanism is effective in older adults Administration of INNA-051 to older adults (65 years old) in a Phase 1 study was well-tolerated and increased important antiviral host-defence pathways Pre-clinical data demonstrated reduced influenza virus dissemination to the lungs of aged mice, consistent with results from studies in […]
ENA Respiratory Receives US$5m Investment from Flu Lab to Support Clinical Development of Novel Intranasal Antiviral Host Defence Immune Enhancer, INNA-051
Melbourne, Australia, 10 February 2025 – ENA Respiratory, a clinical-stage pharmaceutical company developing antiviral host defence immune enhancers to minimize the impact of viral respiratory infections, announces today it has received a US$5 million investment from Flu Lab. Flu Lab, a California-based organization founded to advance innovative approaches for the prevention and treatment of influenza, […]
ENA Respiratory Publishes Review of Development of Novel Intranasal Antiviral Host Defense Immune Enhancer INNA-051 in Antiviral Research
Publication comes as the prevalence of respiratory infections continues to rise worldwide Melbourne, Australia, 28 January 2025 – ENA Respiratory, a clinical-stage pharmaceutical company developing antiviral host defense immune enhancers to minimize the impact of respiratory viral infections in at-risk populations, announces today the publication of an invited review of the preclinical and clinical development […]